{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:03:46Z","timestamp":1777356226531,"version":"3.51.4"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2007,11,27]],"date-time":"2007-11-27T00:00:00Z","timestamp":1196121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Treatment of vitiligo is a challenge, especially in children. Recently, topical calcineurin inhibitors have been introduced in the management of vitiligo, but significant repigmentation is not achieved except on the face. Large pretibial lesions of a 15\u2010year\u2010old female with progressive vitiligo were treated twice daily over six months with 0.1% tacrolimus ointment on the right and 1% pimecrolimus cream on the left side without effect. Additional overnight occlusion with polyurethane and hydrocolloid foils during the following 18 months led to substantial repigmentation on both sides (tacrolimus\u2010treated side, 88% repigmented area; pimecrolimus\u2010treated side, 73%). Tacrolimus serum levels measured at four different time points did not exceed 1.8 ng\/ml. This case report on a direct comparison of topical tacrolimus and pimecrolimus in vitiligo shows that on the shins considerable improvement could be induced with both agents only by additional long\u2010term occlusion and that tacrolimus was somewhat more effective than pimecrolimus.<\/jats:p>","DOI":"10.1111\/j.1610-0387.2007.06455.x","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T00:28:04Z","timestamp":1196728084000},"page":"383-385","source":"Crossref","is-referenced-by-count":13,"title":["Repigmentation of pretibial vitiligo with calcineurin inhibitors under occlusion"],"prefix":"10.1111","volume":"6","author":[{"given":"Anke","family":"Hartmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva\u2010Bettina","family":"Br\u00f6cker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,12,17]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02154.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464010-00006"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.062"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.5.581"},{"key":"e_1_2_5_6_2","first-page":"88","article-title":"Topical 0","volume":"15","author":"Coskun B","year":"2005","journal-title":"05% clobetasol propionate versus 1 % pimecrolimus ointment in vitiligo"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.12.031"},{"key":"e_1_2_5_8_2","first-page":"2006","article-title":"Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double\u2010blind, vehicle\u2010controlled study","volume":"4","author":"Dawid M","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_5_9_2","first-page":"174","article-title":"Tacrolimus\u2010ointment (Protopic) 0","volume":"3","author":"Hartmann A","year":"2005","journal-title":"1% in adult patients with vitiligo: results of a placebo-controlled 12-months prospective study"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-199207000-00007"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.8.999"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02554.x"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78962-5"},{"key":"e_1_2_5_14_2","unstructured":"Prograf 5 mg\/ml. Astellas Pharma GmbH Fachinformation April 2006."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.06.013"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1610-0387.2007.06455.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1610-0387.2007.06455.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T11:19:22Z","timestamp":1695727162000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1610-0387.2007.06455.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,17]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1610-0387.2007.06455.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1610-0387.2007.06455.x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,17]]}}}